# Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto

Source: https://onco.cc/trials/nct06158841/  
OnCo record `nct06158841` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Carfilzomib, Pomalidomide, Elotuzumab in multiple myeloma, run by AbbVie, active and no longer recruiting.

## Summary

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT06158841 by AbbVie, with 421 participants enrolled, started 2024-05-19 and due to reach its primary completion in 2027-12. Interventions recorded: Etentamig, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06158841
- Phase: 3
- Setting: A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
- Sponsor: AbbVie
- Enrolled: 421

## Sources

- ClinicalTrials.gov NCT06158841: https://clinicaltrials.gov/study/NCT06158841

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Bortezomib](https://onco.cc/drugs/bortezomib/), [Carfilzomib](https://onco.cc/drugs/carfilzomib/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Elotuzumab](https://onco.cc/drugs/elotuzumab/), [Pomalidomide](https://onco.cc/drugs/pomalidomide/), [Selinexor](https://onco.cc/drugs/selinexor/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct06158841.json